Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation...
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing AG
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing AG
Subjects
More information
Scope and Contents
Contents
The development of tyrosine kinase inhibitors (TKI) represents a major milestone in oncology. However, their use has been found to be associated with serious toxicities that impinge on various vital organs including the heart. Sixteen TKIs have been approved for use in oncology as of 30 September 2012, and a large number of others are in developmen...
Alternative Titles
Full title
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1500789730
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1500789730
Other Identifiers
ISSN
0114-5916
E-ISSN
1179-1942
DOI
10.1007/s40264-013-0047-5
